Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: Case-control study and meta-analysis

European Journal of Endocrinology

Volumn 163, Issue 3, 2010, Pages 427-434

  Dora, José Miguel ^a   Machado, Walter Escouto ^a   Rheinheimer, Jakeline ^a   Crispim, Daisy ^a   Maia, Ana Luiza ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; IODIDE PEROXIDASE; METFORMIN; SULFONYLUREA DERIVATIVE; TYPE 2 DEIODINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC DIET; EXERCISE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ADULT; AGED; ALANINE; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HOMOZYGOTE; HUMANS; IODIDE PEROXIDASE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SINGLE-BLIND METHOD; THREONINE;

EID: 77956292229     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0419     Document Type: Article

References (40)

1. Bianco AC, Maia AL, Da Silva WS & Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. Bioscience Reports 2005 25 191-208.
2. Croteau W, Davey JC, Galton VA & St Germain DL. Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. Journal of Clinical Investigation 1996 98 405-417. (Pubitemid 26255740)
3. Itagaki Y, Yoshida K, Ikeda H, Kaise K, Kaise N, Yamamoto M, Sakurada T & Yoshinaga K. Thyroxine 50-deiodinase in human anterior pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1990 71 340-344. (Pubitemid 20261818)
4. Salvatore D, Tu H, Harney JW & Larsen PR. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. Journal of Clinical Investigation 1996 98 962-968. (Pubitemid 26293314)
5. Wagner MS, Morimoto R, Dora JM, Benneman A, Pavan R & Maia AL. Hypothyroidism induces type 2 iodothyronine deiodinase expression in mouse heart and testis. Journal of Molecular Endocrinology 2003 31 541-550. (Pubitemid 38054524)
6. Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC & Maia AL. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2005 90 3472-3478.
7. Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC & Kim BW. Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-γ agonists in skeletal myocytes. Endocrinology 2009 150 1976-1983.
8. Heemstra KA, Soeters MR, Fliers E, Serlie MJ, Burggraaf J, Van Doorn MB, Van Der Klaauw AA, Romijn JA, Smit JW, Corssmit EP & Visser TJ. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. Journal of Clinical Endocrinology and Metabolism 2009 94 2144-2150.
9. 3 in euthyroid humans. Journal of Clinical Investigation 2005 115 2524-2533.
10. Coppotelli G, Summers A, Chidakel A, Ross JM & Celi FS. Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5′ UTR of the gene. Thyroid 2006 16 625-632.
11. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR & Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the β-3-adrenergic receptor. Diabetes 2002 51 880-883.
12. Peeters RP, Van Toor H, Klootwijk W, De Rijke YB, Kuiper GG, Uitterlinden AG & Visser TJ. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 2880-2888.
13. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, Van Der Wijk HJ, Kroon HM, Nakajima M, Ikegawa S, Uitterlinden AG, Van Meurs JB, Van Der Deure WM, Visser TJ, Seymour AB, Lakenberg N, Van Der Breggen R, Kremer D, Van Duijn CM, Kloppenburg M, Loughlin J & Slagboom PE. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Human Molecular Genetics 2008 17 1867-1875.
14. Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA & Williams GH. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 2007 49 461-466. (Pubitemid 46263228)
15. Chistiakov DA, Savost'anov KV & Turakulov RI. Screening of SNPs at 18 positional candidate genes, located within the GD-1 locus on chromosome 14q23-q32, for susceptibility to Graves' disease: a TDT study. Molecular Genetics and Metabolism 2004 83 264-270.
16. Guo TW, Zhang FC, Yang MS, Gao XC, Bian L, Duan SW, Zheng ZJ, Gao JJ, Wang H, Li RL, Feng GY, St Clair D & He L. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. Journal of Medical Genetics 2004 41 585-590.
17. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM & Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1623-1629.
18. Heemstra KA, Hoftijzer H, Van Der Deure WM, Peeters RP, Hamdy NA, Pereira A, Corssmit EP, Romijn JA, Visser TJ & Smit JW. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turn-over and decreased femoral neck bone mineral density. Journal of Bone and Mineral Research 2010 25 1385-1391.
19. Weinstein SP, O'Boyle E & Haber RS. Thyroid hormone increases basal and insulin-stimulated glucose transport in skeletal muscle. The role of GLUT4 glucose transporter expression. Diabetes 1994 43 1185-1189.
20. Mentuccia D, Thomas MJ, Coppotelli G, Reinhart LJ, Mitchell BD, Shuldiner AR & Celi FS. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid 2005 15 1223-1227.
21. Maia AL, Dupuis J, Manning A, Liu C, Meigs JB, Cupples LA, Larsen PR & Fox CS. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Thyroid 2007 17 199-202.
22. Grarup N, Andersen MK, Andreasen CH, Albrechtsen A, Borch-Johnsen K, Jorgensen T, Auwerx J, Schmitz O, Hansen T & Pedersen O. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danishwhite subjects. Journal of Clinical Endocrinology and Metabolism 2007 92 363-366.
23. Stolerman ES & Florez JC. Genomics of type 2 diabetes mellitus: implications for the clinician. Nature Reviews. Endocrinology 2009 5 429-436.
24. Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, Santos K, Crispim D, Roisemberg I, Krolewski AS & Gross JL. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 2005 54 3326-3330.
25. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010 33 S11-S61.
26. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T & Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000 23 57-63.
27. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, De Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostrom KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, Jorgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ, Sandbaek A, Shields B, Sjogren M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso I, Hattersley AT, Collins FS, Groop L, Mccarthy MI, Boehnke M & Altshuler D. Metaanalysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 2008 40 638-645.
28. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
29. Bax L, Yu LM, Ikeda N, Tsuruta H & Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Medical Research Methodology 2006 6 50.
30. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, Von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, Van Duijn C, Mclaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A & Birkett N. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. PLoS Medicine 2009 6 e22.
31. Moher D, Liberati A, Tetzlaff J & Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009 6 e1000097.
32. Stroup DF, Berlin JA, Morton SC, Olkin I,Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA & Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. Journal of the American Medical Association 2000 283 2008-2012.
33. Scheidegger K, O'Connell M, Robbins DC & Danforth E Jr. Effects of chronic b-receptor stimulation on sympathetic nervous system activity, energy expenditure, and thyroid hormones. Journal of Clinical Endocrinology and Metabolism 1984 58 895-903.
34. Al-Adsani H, Hoffer LJ & Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. Journal of Clinical Endocrinology and Metabolism 1997 82 1118-1125.
35. Re RN, Kourides IA, Ridgway EC, Weintraub BD & Maloof F. The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. Journal of Clinical Endocrinology and Metabolism 1976 43 338-346.
36. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P & Larsen PR. Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate- responsive human type 2 iodothyronine deiodinase gene. Endocrinology 2000 141 229-237.
37. Celi FS. Brown adipose tissue - when it pays to be inefficient. New England Journal of Medicine 2009 360 1553-1556.
38. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, Mccarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, Mccarroll SA & Visscher PM. Finding the missing heritability of complex diseases. Nature 2009 461 747-753.
39. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L & Lander ES. The common PPARg Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 2000 26 76-80.
40. De Jong FJ, Peeters RP, Den Heijer T, Van Der Deure WM, Hofman A, Uitterlinden AG, Visser TJ & Breteler MM. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. Journal of Clinical Endocrinology and Metabolism 2007 92 636-640.